Anti-Human CD195 (CCR5) [Clone HEK/1/85a/7a] – Purified in vivo GOLD™ Functional Grade

The clone HEK/1/85a/7a is a rat monoclonal antibody widely used for in vivo studies in mice to target and functionally block human CCR5 (CD195), a chemokine receptor expressed primarily on human memory T cells, macrophages, and immature dendritic cells.

Common in vivo applications in mice include:

• Blocking or neutralizing human CCR5 function in humanized mouse models, especially those engineered to express human CCR5, to study immune cell trafficking, inflammatory responses, and disease mechanisms where CCR5 plays a role.
• Investigating HIV-1 infection mechanisms: Since CCR5 is a principal co-receptor for HIV-1 entry into cells, clone HEK/1/85a/7a is used to prevent HIV-1 from infecting humanized mice or to evaluate CCR5’s role in viral pathogenesis.
• Characterizing inflammatory and autoimmune diseases: By inhibiting CCR5 activity, researchers assess how CCR5 influences immune cell migration and disease progression in conditions like diabetes or cancer in models expressing human CCR5.
• Testing potential therapeutics: Used as a functional-grade antibody, it serves in preclinical evaluation of CCR5-targeted treatments and antibody therapies for diseases where CCR5 signaling is pathogenic.

Additional relevant details:

• This antibody is specifically purified for in vivo use, usually with ultra-low endotoxin levels and high batch consistency to ensure safety and reproducibility in mouse models.
• Unlike standard research antibodies, it is formulated to minimize immunogenicity and adverse effects in live animals.
• Its specificity is to human CCR5, so its in vivo use in mice is restricted to humanized or transgenic animals carrying the human receptor.

In summary, clone HEK/1/85a/7a enables selective manipulation and study of human CCR5 biology in vivo, notably in immunology, infectious disease, and therapeutic research using mouse models engineered to possess human immune system components.

In the literature, several antibodies and proteins are commonly used alongside HEK/1/85a/7a, which targets human CD195 (CCR5). These include:

• Anti-CD4 Antibodies: Frequently used in studies involving immune cell trafficking and HIV research, similar to CCR5.
• Anti-G Protein Antibodies: These are involved in various cellular signaling pathways and are often studied in conjunction with CCR5 for their roles in immune responses.
• Anti-HEK 293T Cell Line Antibodies: These are used for specific applications like ELISA and WB, targeting proteins expressed by HEK 293T cells, which are a variant of HEK 293 cells capable of episomal replication.
• GAPDH Antibodies: Used as a loading control in many protein analyses, GAPDH is a common marker for maintaining experimental consistency.
• HEK293-EBNA1 Antibodies: Utilized for cell line characterization, specifically those expressing the Epstein-Barr nuclear antigen 1, which aids in stable gene expression.

These antibodies are employed in various research contexts, including cellular biology, immunology, and molecular biology studies.

The key findings from scientific literature citing clone HEK/1/85a/7a focus on its role as a rat monoclonal antibody specific for human CCR5 (CD195), a chemokine receptor central to several immunological and virological applications.

Essential context and scientific contributions:

• Reliable detection and quantification of human CCR5: Clone HEK/1/85a/7a is widely used to specifically identify and measure CCR5 expression on human cells, crucial for basic and clinical research in immunology and virology.
• Support for HIV research: As CCR5 functions as a coreceptor for HIV-1 entry (mediating the fusion of viral and host cell membranes), this clone has advanced the understanding of HIV pathogenesis and mechanisms of infection by enabling precise cell profiling and quantification of CCR5.
• Characterization of immune cell populations: The antibody is commonly used in flow cytometry (FACS), immunofluorescence (IF), and functional assays to phenotype memory T cells, macrophages, and dendritic cells—all key CCR5-expressing subsets involved in immune responses.
• Investigation of inflammation and malignancy: CCR5’s role in mediating chemotaxis—cell movement in response to chemokines such as CCL3 (MIP-1α), CCL4 (MIP-1β), and RANTES—makes the clone valuable for delineating inflammatory processes and studying tumor-associated immune cell dynamics.
• Broader disease relevance: Recent literature also implicates CCR5, and thus research using this clone, in a variety of other human diseases beyond HIV—including infectious, inflammatory, and oncological conditions.

Technical information:

• Specificity: Clone HEK/1/85a/7a recognizes an extracellular epitope on human CCR5, ensuring specificity and reproducibility across applications.
• Applications: It is validated for use in flow cytometry, immunofluorescence, and functional cell-based assays.
• Host and format: Generated in rat; available as purified, unconjugated, or fluorophore-conjugated preparations for diverse experimental protocols.
• Immunogen: Produced by immunizing with CHO (Chinese Hamster Ovary) cells transfected with human CCR5, ensuring high affinity and specificity for the native antigen.

Summary of impact:

• The primary scientific value of clone HEK/1/85a/7a lies in enabling reproducible, sensitive detection of CCR5 across many immunological and virological studies.
• It has directly supported research into HIV/AIDS, immune cell profiling, and the investigation of CCR5 in inflammation and cancer.
• By providing a trusted tool for characterizing CCR5, the clone underpins both foundational immunology research and translational projects in infectious and inflammatory disease.

No major controversies or conflicting viewpoints about this clone’s role or utility were identified in the current scientific literature.

Dosing regimens for clone HEK/1/85a/7a (an anti-human CCR5 monoclonal antibody) in mouse models are not explicitly standardized and appear to be highly dependent on the specific application, mouse strain, and experimental design. Available data from commercial sources and technical datasheets offer general guidance but emphasize the need for per-experiment optimization:

• Flow Cytometry (FC): The suggested starting concentration is ≤1.0 μg per 10⁶ cells in 100 μl.
• Other Applications: Investigators are advised to titrate the antibody and determine the optimal working dilution for their model and application. The specific dosing regimen may need to be adjusted based on factors such as detection sensitivity, background, and the assay format.
• Lot-Specific Variation: Product datasheets may include updated recommendations or protocol variations, reinforcing the need for pilot titration in each model.

No published data currently specify distinct dosing regimens for different mouse backgrounds (e.g., BALB/c vs. C57BL/6) or for in vivo blocking versus detection uses in immunological studies. Instead, best practice requires empirical titration and method optimization for each distinct mouse model and experiment.

Summary Table: HEK/1/85a/7a Antibody Dosing Guidance

Key Point:
Strict dosing regimens for HEK/1/85a/7a across different mouse models are not established in the literature; protocols emphasize methodical titration and per-study optimization.